Addex Therapeutics Ltd. (ADXN)

NASDAQ: ADXN · IEX Real-Time Price · USD
0.800
-0.000 (-0.01%)
At close: Sep 30, 2022 4:00 PM
0.780
-0.020 (-2.48%)
After-hours: Sep 30, 2022 7:03 PM EDT
-0.01%
Market Cap 7.31M
Revenue (ttm) 1.58M
Net Income (ttm) -22.18M
Shares Out 9.14M
EPS (ttm) -3.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,025
Open 0.820
Previous Close 0.800
Day's Range 0.775 - 0.820
52-Week Range 0.680 - 9.397
Beta 1.76
Analysts Sell
Price Target 0.87 (+8.8%)
Earnings Date Aug 18, 2022

About ADXN

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and col... [Read more...]

Industry Biotechnology
Founded 2002
CEO Tim Dyer
Employees 26
Stock Exchange NASDAQ
Ticker Symbol ADXN
Full Company Profile

Financial Performance

In 2021, ADXN's revenue was 2.92 million, a decrease of -19.28% compared to the previous year's 3.61 million. Losses were -15.35 million, 19.4% more than in 2020.

Financial numbers in CHF Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ADXN stock is "Sell." The 12-month stock price forecast is 0.87, which is an increase of 8.78% from the latest price.

Price Target
$0.87
(8.78% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference

Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announ...

1 week ago - GlobeNewsWire

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Misses Revenue Estimates

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -110.71% and 63.53%, respectively, for the quarter ended June 2022.

1 month ago - Zacks Investment Research

Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR

1 month ago - GlobeNewsWire

Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders

Addex to Receive CHF850,000 ($900,000) of Additional Funding ; Addex 's Reserved Indications Expanded to include Chronic Cough

1 month ago - GlobeNewsWire

Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022

Geneva, Switzerland, August 12 , 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today an...

1 month ago - GlobeNewsWire

Addex Completes $4.2 Million Equity Financing

Ad Hoc Announcement Pursuant to Art. 53 LR

2 months ago - GlobeNewsWire

Addex Raises $4.2 million in Equity Financing

Ad Hoc Announcement Pursuant to Art. 53 LR

2 months ago - GlobeNewsWire

Why Is Addex Therapeutics (ADXN) Stock Up 100% Today?

Addex Therapeutics is usually under the radar on Wall Street, but today ADXN stock is moving fast on the heels of a critical company update. The post Why Is Addex Therapeutics (ADXN) Stock Up 100% Today?

2 months ago - InvestorPlace

What's Happening With Addex Therapeutics Shares Today

Addex Therapeutics Ltd (NASDAQ: ADXN) shares are surging after reducing the nominal value of its issued, authorized, and conditional share capital from CHF 1.00 to CHF 0.01 following the expiration of a...

2 months ago - Benzinga

Addex Completes Reduction in Nominal Value of Shares

Ad Hoc Announcement Pursuant to Art. 53 LR

2 months ago - GlobeNewsWire

Addex Provides Corporate Update and Financial Guidance

Ad Hoc Announcement Pursuant to Art. 53 LR

2 months ago - GlobeNewsWire

Addex (ADXN) Terminates Parkinson's-Related Dyskinesia Study

Addex (ADXN) terminates the phase IIb/III study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease. Shares fall.

3 months ago - Zacks Investment Research

Why Shares Of Addex Therapeutics Are Falling Today

Shares of small-cap penny stock Addex Therapeutics Ltd. (NASDAQ: ADXN) are trading lower after the company terminated its Phase 2b/3 study of Dipraglurant for dyskinesia associated with Parkinson's dise...

3 months ago - Benzinga

Addex Stops Parkinson's-Associated Dyskinesia Trial - Read Here Why

Addex Therapeutics Ltd (NASDAQ: ADXN) has terminated the Phase 2b/3 study of dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients.  Data reado...

3 months ago - Benzinga

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to...

COVID-19 related challenges negatively impacted patient recruitment

3 months ago - GlobeNewsWire

Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

Ad Hoc Announcement Pursuant to Art. 53 LR

4 months ago - GlobeNewsWire

Addex Announces Participation in the H.C. Wainwright Global Investment Conference

Geneva, Switzerland , May 1 9 , 202 2   - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...

4 months ago - GlobeNewsWire

Addex Announces Participation in the 22nd Bio€quity Europe Conference

Geneva, Switzerland , May 1 3 , 202 2   - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...

4 months ago - GlobeNewsWire

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR

4 months ago - GlobeNewsWire

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q1 Loss, Misses Revenue Estimates

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -86.54% and 49.61%, respectively, for the quarter ended March 2022.

4 months ago - Zacks Investment Research

Addex Reports Q1 2022 Financial Results

Ad Hoc Announcement Pursuant to Art. 53 LR

4 months ago - GlobeNewsWire

Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Top-line Data Schedule d to Report in Q2 2022

5 months ago - GlobeNewsWire

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Upgraded to Buy: What Does It Mean for the Stock?

Addex Therapeutics Ltd. Sponsored ADR (ADXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6 months ago - Zacks Investment Research

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q4 Loss, Lags Revenue Estimates

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -25.76% and 16.29%, respectively, for the quarter ended December 2021.

6 months ago - Zacks Investment Research

Addex Reports Full Year 2021 Financial Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR

6 months ago - GlobeNewsWire